Our Episodes
Listen to our episodes, read our episode shownotes, and review our references all on your favorite podcast-streaming platforms:
Links to all of our episodes, the shownotes, and references can also be found below.
Thanks so much for tuning in; We are are so glad you are here.
Episode 089: Prostate Cancer Series, Pt. 6- Treatment for Met. Castrate Sensitive Prostate Cancer
Episode 089: Prostate Cancer Series, Pt. 6 - Systemic Treatment for Metastatic Castrate Sensitive Prostate Cancer
This week, we continue our discussion about metastatic castrate sensitive prostate cancer. Spoiler alert: there is not good guidance or biomarkers that help us pick one regimen over another. In this episode, we go through the data, our critical appraisal of the data, and some things to consider when selecting one regimen over another.
As a refresher, be sure to check out our Pharmacology Episode and our introductory episodes, as we will be building on these concepts.
Episode 088: Prostate Cancer Series, Pt. 5 - Systemic Treatment for Localized Prostate Cancer
Episode 088: Prostate Cancer Series, Pt. 5 - Systemic Treatment for Localized Prostate Cancer
As we continue our exploration of prostate cancer, we turn our focus to one of the earliest areas where medical oncologists are commonly involved: systemic therapy for non-metastatic prostate cancer. In this episode, we will review how to risk stratify localized prostate cancer, differences in FDA-approved prostate-specific PET tracers, how to evaluate for biochemical recurrence following surgical and radiation based treatments for localized prostate cancer, and when to consider utilizing systemic therapy in non-metastatic disease.
Episode 087: Prostate Cancer Series: Pt. 4- Radiation Oncology in Prostate Cancer
Episode 087: Prostate Cancer Series: Pt. 4- Radiation Oncology in Prostate Cancer
Last, but not least, in our multidisciplinary discussions regarding the management of prostate cancer, we are thrilled to present a special episode featuring soon-to-be attending Radiation Oncologist Dr. Jacob Hall. Dr. Hall is a senior Radiation Oncology resident and Chief Resident at UNC-Chapel Hill. Today, he helps us better understand patient selection for radiation and helps define key terms.
As a reminder, we previously discussed the fundamentals of Radiation Oncology with Dr. Evan Osmundson in Episode 027!
Episode 086: Prostate Cancer Series: Pt. 3- Surgical Approaches to Prostate Cancer
Episode 086: Prostate Cancer Series: Pt. 3 - Surgical Approaches to Prostate Cancer
In our next episode, we are joined by Dr. Sanjay Patel, a urologic oncologist from the Stephenson Cancer Center at the University of Oklahoma, who also happens to be Vivek’s older brother! We discuss the management of prostate cancer from the perspective of our urology colleagues. As medical oncologists, these are conversations and decisions that we are almost never a part of, as they are being had often before patients ever see us. It was so helpful to get to hear how Dr. Patel thinks about his patients!
Episode 085: Prostate Cancer Series: Pt. 2. - Pharmacology
Episode 085: Prostate Cancer Series: Pt. 2. - Pharmacology
This week, we chat with Vineetha Thomas, PharmD, BCCCP, BCOP who is a clinical pharmacist specializing in genitourinary oncology at the Stevenson Cancer Center at the University of Oklahoma. In this episode, we discuss the ins-and-outs of how Dr. Thomas thinks about the various drugs available to treat prostate cancer and how she counsels her patients.
Thanks to our friends at the Pharmacy Podcast Network for connecting us with Dr. Thomas!
Episode 084: Prostate Cancer Series: Pt. 1 - Introduction
Episode 084: Prostate Cancer Series: Pt. 1 - Introduction
Prostate cancer is one of the common cancers diagnosed each year in males. In this new series, we will go through the ins-and-outs of this disease. As medical oncologists, there is so much more to prostate cancer than we see. In our future episodes, we will also highlight the important role of pharmacists, radiation oncologists, and urologists in disease management!
Episode 083: Pharmacology 101: Capstone (REBOOT!)
In the final episode in our reboot of Pharmacology 101, we sit down with Renee McAlister, PharmD, BCOP to learn more about the nuances of pharmacology from an expert that does this day in and day out.
Episode 082: Pharmacology 101: Part 2 (REBOOT!)
Episode 082: Pharmacology 101: Part 2 (REBOOT!)
As we prepare for another round oncology series in the weeks to come, we thought we would pause and go back to to the basics. We continue on our Pharmacology 101 series this week. This is such a high yield episode for anyone who cares for patients receiving therapy for their cancer!
Episode 081: Pharmacology 101: Part 1 (REBOOT!)
As we prepare for another round oncology series in the weeks to come, we thought we would pause and go back to to the basics. We previously released this episode as Episode 020. This episode is a must-listen for anyone who talks to patients about chemotherapy!
Episode 080: Heme Consult Series: When anticoagulation fails, Part 2
Episode 080: Heme Consult Series: When anticoagulation fails, Part 2
We started this conversation last week! This week, we focus on how to approach warfarin and enoxaparin failure! Be sure to check out Episode 079 for part 1!
Episode 079: Heme Consult Series: When anticoagulation fails, Part 1
Episode 079: Heme Consult Series: When anticoagulation fails, Part 1
It’s time for another Heme Consult series, this time focusing on another common question we see in the hospital and in clinic: “is this anticoagulation failure?”
In this two-part series, we break down how we approach the workup to determine exactly this. In this episode, we discuss "DOAC failure".
Episode 078: Management of relapsed diffuse large B-cell lymphoma (DLBCL) - Part 2
Episode 078: Management of relapsed diffuse large B-cell lymphoma (DLBCL) - part 2
In this FINAL episode of our DLBCL series, we build on our conversation from last week, focusing on the management of relapsed DLBCL. If you have not done so already, we recommend you check out Episode 077!
Episode 077: Management of relapsed diffuse large B-cell lymphoma (DLBCL) - part 1
Episode 077: Management of relapsed diffuse large B-cell lymphoma (DLBCL) - part 1
In our last episode, we discussed our approach to primary refractory DLBCL. This week, we start our conversation about relapsed DLBCL! This is an important and complex discussion, so we have split it into two episodes to help you follow along.
If you have not done so already, we recommend you check out episode 076 for a discussion about the primary refractory setting
Episode 076: Management of primary refractory diffuse large B-cell lymphoma (DLBCL)
Episode 076: Management of primary refractory diffuse large B-cell lymphoma (DLBCL)
This week, we pick up on our discussion about management of DLBCL, focusing on the primary refractory setting. A big part of this discussion is the role of CAR-T therapy. If you have not done so already, we highly recommend you check out episode 075 for the fundamentals of CAR-T before proceeding with this episode!
Episode 075: Intro to CAR-T, Bispecifics (BiTE), and Autologous Transplant
Episode 075: Intro to CAR-T, Bispecifics (BiTE), and Autologous Transplant
In this week’s episode, we pause from our discussion about DLBCL to talk about the fundamentals of CAR-T, BiTE and autologous transplants, which will lay the foundation for subsequent discussions about DLBCL. These therapies are the talk of the town and have changed/will continue to change our approach to hematologic malignancies - definitely an episode you don’t want to miss.
Episode 074: Management of Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Episode 074: Management of Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
In this week’s episode, we delve into the management of advanced stage DLBCL.
If you have not done so, we highly recommend you listen to our hemepath series before proceeding with this episode. Furthermore, if you have not listened to the introduction to DLBCL episode (Episode 072) or our early stage DLBCL episode (Episode 073), we highly recommend doing so, as we will be building on these basics this week.
Episode 073: Management of Early Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Episode 073: Management of Early Stage Diffuse Large B-Cell Lymphoma (DLBCL)
This week, we continue our conversation about DLBCL, this time focusing our attention on the management of early stage disease.
If you have not done so, we highly recommend you listen to our hemepath series before proceeding with this episode. Furthermore, if you have not listened to the introduction to DLBCL episode (Episode 072), we highly recommend doing so, as we will be building on these basics this week.
Episode 072: Introduction to Diffuse Large B-Cell Lymphoma (DLBCL)
Episode 072: Introduction to Diffuse Large B-Cell Lymphoma (DLBCL)
This week, we kick off a new series focusing on diffuse large B-cell lymphoma. In this first episode, we discuss the basics that everyone needs to understand before diving into the management of this disease.
Episode 071: Heme Consults Series: Heparin-induced thrombocytopenia (A deeper dive!)
Episode 071: Heme Consults Series: Heparin-induced thrombocytopenia (A deeper dive!)
We revisit a topic covered previously as part of our “Heme/Onc Emergencies” series: heparin-induced thrombocytopenia (HIT) in Episode 017. As part of our return, we dive deeper into the pathophysiology, principles of diagnosis, and management of HIT to help you to better understand how to approach the question of “is this HIT?” as a Hematology consultant and, more importantly, how to guide management based on your index of suspicion.
Episode 070: Heme Consults Series: Von Willebrand Disease, Part 2
Episode 070: Heme Consults Series: Von Willebrand Disease, Part 2
This week in our hematological consultation series, we continue our discussion on von Willebrand disease (vWD), this time focusing on the type 2 subtypes and we also discuss management.
In case you missed it, we recommend checking out episode 069 for Part I of this vWD series, covering taking a bleeding history and about Type 1 and Type 3 disease.